Finerenone, a non-steroidal mineralocorticoid receptor antagonist, demonstrated reduction in CKD progression and cardiovascular events in patients with type 2 diabetes and CKD in which landmark trial?
- A CREDENCE trial
- B DAPA-CKD trial
- C FIDELIO-DKD trial ✓
- D ADVANCE trial
Correct answer: C. FIDELIO-DKD trial
Explanation
The FIDELIO-DKD trial (2020) demonstrated that finerenone, a selective non-steroidal MRA, significantly reduced the composite of kidney failure, sustained ≥40% eGFR decline, and renal death, as well as cardiovascular events in patients with T2DM and CKD. CREDENCE was the canagliflozin kidney trial; DAPA-CKD tested dapagliflozin in CKD with and without diabetes; ADVANCE tested intensive BP and glucose control. Finerenone's cardiorenal benefit is additive to SGLT2 inhibitors and forms the basis of current quadruple therapy in diabetic CKD.
Reference: Harrison's Principles of Internal Medicine, 21st ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.